News
Life Sciences M&A Values Soar in 2011 May 14, 2012 | Press Release
Life Sciences M&A Activity Heats Up in April, says Burrill & Company May 01, 2012 | Press Release
Burrill & Company Leads $12.9 Million Series E Round In WhiteGlove Health April 16, 2012 | Press Release
See all News
David Wetherell
Managing PartnerDavid Wetherell has spent more than 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. When CMGI, now ModusLink, turned its direction away from the Internet to cleantech venture investing and supply chain management, Mr. Wetherell turned his attention to the life sciences industry. In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. He has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine’s Top 25 investors. He obtained his BA in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Flexible Stenting Solutions, TMune Therapeutics and Quintess.


